With the development of obeticholic acid (OCA) (Pellicciari et al., 2002), a semi-synthetic bile acid analogue and a ligand for FXR, in clinical trials for NASH, FXR has emerged as an attractive drug target for NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.